Utpal Koppikar
Director/Board Member presso C4 THERAPEUTICS, INC.
Patrimonio netto: 203 803 $ in data 29/02/2024
Profilo
Utpal Koppikar is on the board of C4 Therapeutics, Inc.
He previously was Chief Financial Officer for Atara Biotherapeutics, Inc. and Vice President-Corporate & Operations Finance at Gilead Sciences, Inc.
He received an undergraduate degree from the University of Maryland, a graduate degree from Stanford University and an MBA from UCLA Anderson School of Management.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
02/03/2023 | 181 978 ( 0.14% ) | 141 579 $ | 29/02/2024 | |
C4 THERAPEUTICS, INC.
0.01% | 15/06/2023 | 5 667 ( 0.01% ) | 62 224 $ | 29/02/2024 |
Posizioni attive di Utpal Koppikar
Società | Posizione | Inizio |
---|---|---|
C4 THERAPEUTICS, INC. | Director/Board Member | 16/03/2022 |
Precedenti posizioni note di Utpal Koppikar
Società | Posizione | Fine |
---|---|---|
ATARA BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 31/03/2023 |
FLEXION THERAPEUTICS, INC. | Director/Board Member | 19/11/2021 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/06/2018 |
Formazione di Utpal Koppikar
Stanford University | Graduate Degree |
University of Maryland | Undergraduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
C4 THERAPEUTICS, INC. | Health Technology |
ATARA BIOTHERAPEUTICS, INC. | Health Technology |
Aziende private | 1 |
---|---|
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |